SEQUENCE LISTING

<110> Bayer HealthCare AG

<120> Diagnostics and Therapeutics for Diseases Associated with N-Acetylated Alpha-Linked Acidic Dipeptidase-Like 1 (NAALADASE-like1)

<130> BHC 03 01 003

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 2320

<212> DNA

<213> Homo sapiens

<220>

<221> misc feature

<222> (315)..(315)

<223> n=a,c,g,t

<400> 1

gccaagagtc cgcaggatgc agtggacgaa ggtgttgggg ctggggctgg gggctgctgc 60 cctcttgggg ctggggatca tcctcggcca ctttgccatc cccaaaaaag ccaactcact - 120 ggccccccag gacctggacc tggagatcct ggagaccgtc atggggcagc tggatgccca 180 caggateegg gagaacetea gagaactete cagggageea cacetggeet ceageceteg 240 ggatgaggac ctggtgcagc tgctgctgca gcgctggaag gacccagagt caggcctgga 300 ctcggccgag gcctncacgt acgaagtgct gctgtccttc cctagccagg agcagcccaa 360 420 cgtcgtggac atcgtgggcc ccactggggg catcatccac tcctgccacc ggactgagga gaacgtgacc ggggagcaag gggggccaga tgtggtacaa ccctatgctg cctatgctcc 480 ttctggaacc ccacagggcc tcctcgtcta tgccaaccgg ggcgcggaag aagactttaa 540 ggagctacag actcagggca tcaaacttga aggcaccatt gccctgactc gatatggggg 600 660 tgtagggegt ggggeeaagg etgtgaaege tgeeaageae.ggggtagetg gggtgetggt gtacacagac cotgoogaca toaacgatgg gotgagetca cocgacgaaa cotttoocaa 720 ctcctggtac ctgccccct caggagtgga gcgaggctcc tactacgagt attttgggga 780 ccetetgact ccetacette cagecgtece etetteette cgcgtggace ttgccaatgt 840 ctccggattt cccccaattc ctacacagec cattggettc caggatgcaa gagacetget 900 960 ctgtaacctc aacggaactt tggccccagc cacctggcag ggagcactgg gctgccacta 1020 caggttgggt coeggettce ggcctgacgg agacttccca gcagacagcc aggtgaatgt 1080 gagcgtctac aaccgcctgg agctgaggaa ctcttccaac gtcctgggca tcatccgtgg ggctgtggag cctgatcgct acgtgctgta tgggaaccac cgagacagct gggtgcacgg 1140 1200 ggetgtggae cecageagtg geacegeegt ceteetggag etetecegtg teetggggae cctgctgaag aagggcacct ggcgtcctcg cagatcaatc gtgtttgcga gctggggggc 1260

tgaggagttt gggctcattg gctccacgga attcacagaa gagttcttca acaagctgca 1320 ggagcgcacg gtggcctaca tcaacgtgga catctcggtg tttgccaacg ctacccttag 1380 ggtgcagggg acgeccettg tecagagegt cgtettetet gcaaccaaag agatecgete 1440 accaggecet ggegacetga geatetacga caactggate eggtacttea accgeageag 1500 cccggtgtac ggcctggtcc ccagcttggg ttctctgggt gctggcagcg actatgcacc 1560 1620 . cttcgttcac ttcctgggca tctcctccat ggacattgcc tatacctatg accggagcaa gacttcagcc aggatctacc ccacctacca cacagccttt gacacctttg actatgtgga 1680 caagtttttg gaeccgggct tcagcagcca tcaggetgtg gcccggacag cggggagtgt 1740 gatteteegg eteagtgaca gettetteet geeceteaaa gteagtgact acagtgagae 1800 actocgcago ttootgcagg cagoccagca agatottggg gccctgctgg agcagcacag 1860 catcagcctg gggcctctgg tgactgcagt ggagaagttt gaggcagaag ctgcagcctt 1920 gggccaacgc atatcaacac tgcagaaggg cagccctgac cccctgcagg tccggatgct 1980 caatgaccag ttgatgctct tggaacggac ctttctgaac cctagagcct tcccagagga 2040 acgetactae agecatgtge tetgggeace ttegeacggg etcegtagte acatteeggg 2100 gctatccaat gcctgctcca gggccaggga cacagcttct ggatctgaag cttgggctga 2160 ggtccagaga cagctcagca ttgtggtgac agccctggag ggtgcggcag ccaccctgag 2220 gcetgtgget gacetetgae eccagecete tttetteage ectecettta etceggtget 2280 2320 ttatatttac aaagtgcttt gtgtttttta aaagtctttt

<210> 2

<211> 740

<212> PRT

<213> Homo sapiens

<220>

<221> MISC_FEATURE

<222> (100)..(100)

<223> X=any

<400> 2

Met Gln Trp Thr Lys Val Leu Gly Leu Gly Leu Gly Ala Ala Ala Leu · 10 . Leu Gly Leu Gly Ile Ile Leu Gly His Phe Ala Ile Pro Lys Lys Ala

25

Asn Ser Leu Ala Pro Gln Asp Leu Asp Leu Glu Ile Leu Glu Thr Val

40 Met Gly Gln Leu Asp Ala His Arg Ile Arg Glu Asn Leu Arg Glu Leu

55

Ser Arg Glu Pro His Leu Ala Ser Ser Pro Arg Asp Glu Asp Leu Val

85

75 70

Gin Leu Leu Gin Arg Trp Lys Asp Pro Glu Ser Gly Leu Asp Ser

Ala Glu Ala Xaa Thr Tyr Glu Val Leu Leu Ser Phe Pro Ser Gln Glu

105 100

90

Gln Pro Asn Val Val Asp Ile Val Gly Pro Thr Gly Gly Ile Ile His

3/5

		115					120				•	125			
Ser	Cys	His	Arg	Thr	Glu	Glu	Asn	Val	Thr	Gly	Glu	Gln	Gly	Gly	Pro
:	i30					135					140				
Asp .	Val	Val	Gln	Pro	Tyr	Ala	Ala	Tyr	Ala	Pro	Ser	GJA	Thr	Pro	${\tt Gl}{\tt n}$
145					150	•				1,55	•			•	160
Gly :	Leu	Leu	Val	Tyr	Ala	Asn	Arg	Gly	Ala	Glu	Glu	Asp	Phe	Lys	Glu
				165					170					175	
Leu	Gln	Thr	Gln	Gly	Ile	Lys	Leu	GIn	Gly	Thr	Ile	Ala		Thr	Arg
. •			180					185					190		•
Tyr	Gly	Gly	Val	Gly	Arg	Gly	Ala	Lys	Ala	Val	Asn		Ala	Lys	His
		195		•		•	200					205		_	
GJA	Val	Ala	GŢĀ	Val	rea		TYT	Thx	Asp	Pro		Asp	Ile	Asn	Asp
	210		_	_		215			_		220		m	•	D
_	Leu	Ser	Ser	Pro.	•	Glu	Thr	Phe	Pro		ser.	Trp	TYT	ren	
225					230		_			235	m	Db.o	01		240
Pro	Ser	Gly	Val		Arg	GTĀ.	Ser	Tyr		GTI	TYE	Pne	GIY	255	PIO
		_		245			**- 7	D	250	· 6	Dho	A == ~	7757		T.OU
Leu	Thr	Pro		ьeu	PIO	Ата	Val	265	ser.	Ser	Phe	arg	270	voħ	neu
		77- 7	260	01- -	Db.	Dmo	Pro		Bro	wh-	Gln	Pro		G] v	Phe
ALA	ASI	275	Ser		PHE	PLO	280	.rre	FIO		GLA	285		G. J	
G] n	A ex		Ara	Agn	T.O.	T. 211	Cys	Agn	Tæn	Asn	Glv		Leu	Ala	Pro
GIM	290	ALG	n.g	wab			O.Y.D				300				
Δla		ψrn	Gln	Glv	•		GLy	Cvs	His	Tvr		Leu	Gly	Pro	Gly
305				2	310					315	J				320
	Ara	Pro	Asp	Glv		Phe	Pro	Ala	Asp	Ser	Gln	Va1	Asn	Val	Ser
				325	-				330					335	•
Val	Tyr	Asn	Arg	Leu	Glu	Leu	Arg	Asn	Ser	Ser	Asn	Val	Leu	Gly	Ile.
			340					345					350		
11e	Arg	Gly	Ala	Val	Glu	Pro	qeA	Arg	Tyr	Val	Leu	Tyr	Gly	Asn	His
		355	-				360				ı,	365			
Arg	Aşp	Ser	Trp	Val	His	Gly	Ala	Val	Asp	. Pro	Ser	Ser	Gly	Thr	Ala
	370					375	•				380				
Val	Leu	Lev	Glu	Leu	Ser	Arg	Val	rea	Gly	Thr	Leu	Leu	Lys	Lys	Gly
385				٠.	390					. 395	•				400
Thr	Trp	Arg	, Pro	Arg	Arg	Ser	Ile	Val	Phe	Ala	Ser	Trp	Gly	Ala	Glu
				405					410					415	
Glu	Phe	gJ ^ż	Lev	Ile	Gly	Ser	Thx	Glu	Phe	Thr	Glu	Glu			Asn
			420					425					430		
Lys	Lev			Arg	Thr	'Val		Тух	Ile	Asn	Val			Ser	Val
		435					440				_	445			
Phe			ı Ala	Thr	Leu			Gln	Gly	Thr			val	GID	Ser
	450					459			_	_	460				- %
		Phe	e Sei	: Ala			s Glu	. Ile	Arg			Gly	Pro	GIY	Asp
465					470)				475	•				480

Leu Ser Ile Tyr Asp Asn Trp Ile Arg Tyr Phe Asn Arg Ser Ser Pro 490 485 Val Tyr Gly Leu Val Pro Ser Leu Gly Ser Leu Gly Ala Gly Ser Asp 505 Tyr Ala Pro Phe Val His Phe Leu Gly Ile Ser Ser Met Asp Ile Ala 520 Tyr Thr Tyr Asp Arg Ser Lys Thr Ser Ala Arg Ile Tyr Pro Thr Tyr 535 His Thr Ala Phe Asp Thr Phe Asp Tyr Val Asp Lys Phe Leu Asp Pro 555 560 550 Gly Phe Ser Ser His Gln Ala Val Ala Arg Thr Ala Gly Ser Val Ile 565 570 Leu Arg Leu Ser Asp Ser Phe Phe Leu Pro Leu Lys Val Ser Asp Tyr 585 Ser Glu Thr Leu Arg Ser Phe Leu Gln Ala Ala Gln Gln Asp Leu Gly 600 Ala Leu Leu Glu Gln His Ser Ile Ser Leu Gly Pro Leu Val Thr Ala 615 620 Val Glu Lys Phe Glu Ala Glu Ala Ala Ala Leu Gly Gln Arg Ile Ser 635 630 Thr Leu Gln Lys Gly Ser Pro Asp Pro Leu Gln Val Arg Met Leu Asn 645 650 Asp Gln Leu Met Leu Leu Glu Arg Thr Phe Leu Asn Pro Arg Ala Phe 660 665 pro Glu Glu Arg Tyr Tyr Ser His Val Leu Trp Ala Pro Ser His Gly . 680 Leu Arg Ser His Ile Pro Gly Leu Ser Asn Ala Cys Ser Arg Ala Arg . 695 Asp Thr Ala Ser Gly Ser Glu Ala Trp Ala Glu Val Gln Arg Gln Leu 710 Ser Ile Val Val Thr Ala Leu Glu Gly Ala Ala Ala Thr Leu Arg Pro 730 Val Ala Asp Leu 740

<210> 3
<211> 20
<212> DNA
<213> artificial sequence

<220>

<223> forward primer

<400> 3 ctggaaggac ccagagtcag

PCT/EP2004/011011

<210>	4 .		
<211>	20		
<212>	DNA		
<213>	artificial sequence		
<220>	•		
<223>	reverse primer		
<400>	4 `		
taggga	agga cagcagcact	20	
<210>	5		
<211>	19		
<212>	DNA		
<213>	artificial sequence		
-			
<220>			
<223>	probe		
		•	
<400>	5	•	
ctggactcgg ccgaggcct			